TD Cowen Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $95
Medtronic's Buy Rating Justified by Growth in CST Sector and AiBLE's Market Integration
DBS Initiates Medtronic(MDT.US) With Hold Rating, Announces Target Price $90
Medtronic's Hold Rating: Financial Pressures and Market Shifts Impacting Profit Margins and Growth
BofA Securities Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $100
Medtronic Buy Rating Affirmed: Sustained Growth and Strong Pipeline Drive Positive Outlook
Wells Fargo Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $106
Wells Fargo Remains a Buy on Medtronic (MDT)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Harmony Biosciences Holdings (HRMY) and Keros Therapeutics (KROS)
Barclays Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $105
Medtronic Analyst Ratings
Truist Financial Maintains Medtronic(MDT.US) With Hold Rating, Announces Target Price $90
Daiwa Securities Adjusts Price Target on Medtronic to $99 From $92, Maintains Buy Rating
Barclays Maintains Medtronic(MDT.US) With Buy Rating, Raises Target Price to $105
A Quick Look at Today's Ratings for Medtronic(MDT.US), With a Forecast Between $90 to $106
Medtronic Hold Rating Justified by Balanced Growth and Conservative Outlook
Medtronic Price Target Raised to $90.00/Share From $85.00 by Piper Sandler
Argus Research Releases a Buy Rating on Medtronic (MDT)
A Quick Look at Today's Ratings for Medtronic(MDT.US), With a Forecast Between $87 to $106
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Medtronic (MDT)